AC Immune SA reports results for the quarter ended in June - Earnings Summary

AC Immune SA

06/08/2024 14:21

* AC Immune SA  ACIU.OQ  reported a quarterly adjusted loss
of 23
rappen​​ per share for the quarter ended in June, lower than the
same quarter last year, when the company reported EPS of -20
rappen.  The mean expectation of four analysts for the quarter
was for earnings of 27 rappen per share. Wall Street expected
results to range from -20 rappen to 72 cents per share.
    * Revenue was CHF687.00 thousand​; analysts expected zero. 
    * AC Immune SA's reported EPS for the quarter was a loss
of 23
rappen​.
    * The company reported a quarterly loss of CHF22.76 million.
    * AC Immune SA shares had fallen by 12.5% this quarter and
lost 30.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 238.9%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for AC Immune SA is
$8.50 
This summary was machine generated from LSEG data August 6 at
01:21 p.m. UTC. ​All figures in Swiss francs unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      0.27           -0.23          Missed
 Mar. 31 2024      -0.14          -0.18          Missed
 Dec. 31 2023      -0.11          -0.05          Beat
 Sep. 30 2023      0.03           -0.18          Missed